Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122197 · ClinicalTrials.gov registry record · Early Phase 1
Study of Letrozole in Recurrent Gliomas
A Early Phase 1 study, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT03122197 is a Early Phase 1 study that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 39 participants.
The verdict
NCT03122197, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
Interventions
- DRUG Temozolomide
- DRUG Letrozole Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122197
The ClinicalTrials.gov registry entry for NCT03122197 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT03122197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122197 about?
NCT03122197 is a clinical study titled "Study of Letrozole in Recurrent Gliomas". The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.
What is the current status of trial NCT03122197?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2017-05-16. Estimated completion is 2027-12.
What interventions are being tested in trial NCT03122197?
The interventions under investigation include: Temozolomide (DRUG), Letrozole Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03122197?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.